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Abstract
Objective This article presents alternative parental health spillover quantiication methods in the context of a randomised 
controlled trial comparing family therapy with treatment as usual as an intervention for self-harming adolescents, and dis-
cusses the practical limitations of those methods.
Methods The trial followed a sample of 754 participants aged 11–17 years. Health utilities are measured using answers to the 
EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) for the adolescent and the Health Utility Index (HUI2) for one parent at baseline, 
6 and 12 months. We use regression analyses to evaluate the association between the parent’s and adolescent’s health utilities as 
part of an explanatory regression model including health-related and demographic characteristics of both the adolescent and the 
parent. We then measure cost-efectiveness over a 12-month period as mean incremental cost-efectiveness ratios using various 
spillover quantiication methods. We propose an original quantiication based on the use of a household welfare function along 
with an equivalence scale to generate a health gain within the family to be added to the adolescent’s quality-adjusted life-year gain.
Results We ind that the parent’s health utility increased over the duration of the trial and is signiicantly and positively asso-
ciated with adolescent’s health utility at 6 and 12 months but not at baseline. When considering the adolescent’s health gain 
only, the incremental cost-efectiveness ratio is £40,453 per quality-adjusted life-year. When including the health spillover 
to one parent, the incremental cost-efectiveness ratio estimates range from £27,167 per quality-adjusted life-year to £40,838 
per quality-adjusted life-year and can be a dominated option depending on the quantiication method used.
Conclusion According to the health spillover quantiication method considered, the incremental cost-efectiveness ratios 
vary from within the National Institute for Health and Care Excellence (NICE) cost-efectiveness threshold range to not 
being cost-efective.
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Key Points 
Parental health spillover varies with treatment arms and 
follow-up points, and is independent from the adoles-
cent’s health improvement.
Health spillover can be measured using a household 
welfare function along with an equivalence scale to gen-
erate a health gain within the family to be added to the 
patient’s quality-adjusted life-year gain.
According to the health spillover quantiication method 
considered, the incremental cost-efectiveness ratio var-
ies from being cost-efective to not being cost-efective.
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1 Introduction
Self-harm is commonly deined in the UK and Europe as 
any form of non-fatal self-poisoning or self-injury (such 
as cutting, taking an overdose, hanging, self-strangulation, 
jumping from a height and running into traic), regardless 
of the motivation or degree of intention to die. This deini-
tion would include US deinitions of non-suicidal self-injury 
and suicidal behaviour. Self-harm in adolescents is a major 
public health issue with one in ten adolescents self-harming 
each year [1]. Individuals with mental disorders are heavy 
users of public health services and require emotional support 
and care from their family [2, 3]. Their disorders are likely 
to afect other family members’ health and own healthcare 
needs, especially because individuals with mental health 
conditions face elevated rates of all-cause mortality and this 
places a huge burden of costs and life-years lost on the fam-
ily and the community [4].
It appears that the magnitude of spillovers on the health 
of other family members is the greatest in parents of ill chil-
dren [5, 6]. Beyond the efect of caring for an ill child on 
parents’ health [7], treatments that are provided to a self-
harming child may have various spillover efects for the 
family. Indeed, psychotherapeutic treatments such as family-
based therapies are often used with self-harming adolescents; 
they rely on individuals’ relational network, involve parents, 
caregivers, brothers and sisters, or other close relatives and 
friends in the therapies to improve clinical outcomes [8], 
and typically aim at maximizing cohesion, attachment and 
support while moderating parental control [9]. Therapy ses-
sions do not necessarily include all family members, but it is 
expected that they will have an impact beyond the identiied 
patient.
Some prior economic evaluations of psychotherapeutic 
interventions in young people have examined the impact of 
the therapy on the adolescent/child patient and on relatives 
participating in the therapy. These studies collected parents 
or carers’ outcomes and used them as additional outcomes 
of interest in a cost-efectiveness analysis (CEA) [10–12], 
whilst only two studies combined child and parents’ out-
comes. Bodden et al. [13] used a compound summary of 
anxiety-speciic scores of the child, mother and father, as 
part of the sensitivity analyses. Their analysis measured the 
cost-efectiveness per anxiety-free family by including the 
costs related to the child and other family members’ anxi-
ety as self-reported in cost diaries. Cottrell et al. [14] used 
the same data as this article over an 18-month follow-up 
and aggregated quality-adjusted life-years (QALYs) of the 
adolescent and one parent as a sum in a sensitivity analy-
sis. Their application relied on the strong assumption that 
QALYs can be summed across individuals. This assump-
tion has been used in other studies in child health [15] and 
is consistent with research showing beneits to other family 
members involved in mental health family treatment [16, 
17]. However, such considerations require a more thorough 
discussion of the interdependence between the utility func-
tions of the adolescent and the parent, and the most appro-
priate method to include the overall health beneits.
The National Institute for Health and Care Excellence 
(NICE) reference case underlines that the perspective on 
outcomes considers “all direct health efects, whether for 
patients or, when relevant, carers” [18]; however, there is no 
consensus on how these health efects should be measured 
and valued. Wittenberg and Posser [19] ofered a summary 
of the evidence on the measurement and incorporation of 
health spillover of illness on family members or caregiv-
ers across health conditions, as a disutility. In their review, 
methods to measure spillovers included three diferent types: 
(1) a direct measure of disutility of family members; (2) 
a relative measure of family members’ utility with a com-
parison to a control group; or (3) an estimation of the utility 
of family members in a hypothetical scenario in which the 
patient is healthy or does not require caregiving.
In empirical economic evaluation studies, health spillo-
vers have been included either as accrued health beneits 
[20–22] or as an estimated multiplier parameter, which 
adjusts the patient’s health gain with a spillover for the rest 
of a wider network (including parents, carers, spouses and 
other relevant individuals) [23, 24]. Whilst the irst method 
uses a health-related quality of life (HRQoL) questionnaire 
and directly elicited utilities, the multiplier efect is based 
on a regression model using observational or primary data 
collection and consists of two multiplier efects.
In this article, we use data from a multi-centre, individu-
ally randomised controlled trial comparing family therapy 
(FT) with treatment as usual (TAU) as an intervention for 
self-harming adolescents aged 11–17 years [25] as a case 
study. Both the adolescent and one parent1 reported their 
HRQoL as part of the trial across repeated follow-up points. 
We undertake a within-trial CEA incorporating parental 
health spillover efects using alternative quantiication meth-
ods. We add to the growing literature in three ways. First, we 
investigate the association between the health utility of the 
parent and a self-harming adolescent as part of an explana-
tory regression model using the preference-based HRQoL 
scores of both the adolescent and one parent. Second, we 
present a comparative analysis of alternative spillover 
quantiication methods as part of an economic evaluation, 
bringing together the dyadic and the regression-based per-
spectives. Finally, we discuss how health spillovers could be 
adjusted including beneits to the rest of the family using an 
equivalence scale (ES) to adjust parental health gain.
1 The study collected data on the main caregiver, who was either the 
mother (86%) or the father (11%), thus we loosely use the term parent 
in this article.
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2  Self-Harm Intervention: Family Therapy 
(SHIFT) Trial Case Study
The self-harm intervention: family therapy (SHIFT) study 
was a randomised controlled trial conducted in local child 
and adolescent mental health services in Yorkshire, Greater 
Manchester and London for adolescents aged 11–17 years 
who had self-harmed twice. Participants were randomly 
allocated to receive FT or TAU. The objective of the trial 
was to assess whether FT would reduce the number of times 
the adolescents attended hospital with further self-harm. The 
trial results are reported elsewhere [14].
Personal characteristics were collected at baseline includ-
ing the adolescent’s sex, age, and type and number of self-
harm episodes, as well as the sex and age of their parent. 
Additional information was collected on the adolescent’s 
mental health using the Hopelessness Scale for Children 
[26], the parent’s emotion toward the adolescent using the 
Family Questionnaire [27], the parent’s viewpoint on the 
family atmosphere through the McMaster Family Assess-
ment Device [28] and the parents’ General Health Question-
naire (GHQ-12) [29]. All these measurements are deined 
in Table 1. The adolescent’s HRQoL was measured by the 
EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) [30] whilst the 
parent’s HRQol was determined by the Health Utility Index 
(HUI2) [31, 32]. The original research proposal considered 
HUI2 as the HRQoL measure for both the parent and the ado-
lescent following the NICE guidelines at the time [33, 34]. 
However, we carried out a pilot study [35] on a sample of 49 
adolescents aged 11–18 years to test the ability of children to 
deal with the concepts and language used in the EQ-5D-3L 
and HUI2. We found that EQ-5D-3L had the least amount of 
missing data and presented limited problematic wording for 
that age group; therefore, the EQ-5D-3L was eventually used 
to measure the HRQoL of adolescents in the trial. However, 
the parents’ HRQoL instrument was not changed.
An adolescent’s responses to the EQ-5D-3L were con-
verted into health-state utility scores using national tarif 
values [36]. Similarly, a parent’s responses to HUI2 were 
converted into health-state utility values [32, 37]. The area 
under the curve approach was used to calculate QALYs for 
the adolescent and the parent.
Resource use of health services was self-reported by the 
adolescent and/or his or her parent. Accident and emergency 
visits and inpatient stays of the adolescent were available 
from National Health Service digital records. Resource use 
was combined with national unit costs distinguishing, where 
possible, by a self-harm and not self-harm-related event 
leading to hospitalisation [38]. Psychotropic medication 
costs were calculated using trial medication records. The 
intervention costs were calculated separately for each treat-
ment arm using information on the type and duration of the 
therapies sessions available from the trial records [14, 39].
Eight hundred and thirty-two adolescents and their par-
ents were recruited in the trial (417 in TAU and 415 in 
FT). This article focuses on the irst 12-month follow-up, 
thus discounting is not required. Missing utility scores and 
total health and hospital services costs at 6 and 12 months 
were imputed using multiple imputations via chained 
equations [40–42]. Imputations were based on a number 
of demographic and clinical predictors; the process is 
described elsewhere [39]. Missing utility (4%) and clini-
cal scores (3%) at baseline were not imputed. The sample 
used in the main analysis is 731 adolescents and their par-
ent (359 in TAU and 372 in FT). As part of the sensitivity 
analysis, the analysis was also carried out on the complete 
case sample; the sample reduced to 206 adolescents and 
their parent (73 in TAU and 133 in FT).
3  Methods
3.1  Association Between a Parent’s 
and a Self‑Harming Adolescent’s Health
We irst modelled the utility of the parent as a function of 
the adolescent’s HRQoL (utility) in the same period control-
ling for a number of adolescent and parent characteristics. 
Table 1  Description of clinical scores
GHQ General Health Questionnaire
Adolescent Hopelessness Scale for Children: A measure of the degree to which adolescents have negative expectancies about themselves 
and the future. It consists of 17 items with true or false responses, providing a single overall score with higher scores relecting 
greater negative expectations towards the future
Parent Family Questionnaire: A 20-item self-report questionnaire relating to the diferent ways in which families try to cope with every-
day problems. It consists of a single overall score with higher scores indicating greater levels of expressed emotion directed at the 
adolescent by the parent
McMaster Family Assessment Device: A measurement of family functioning across 60 items on six diferent dimensions: Problem 
Solving, Communication, Roles, Afective Responsiveness, Afective Involvement and Behaviour Control. A higher total score is 
indicative of poorer family functioning
GHQ-12: A measure of current mental health focusing on two major areas: the inability to carry out normal functions and the 
appearance of new and distressing experiences. High total scores are indicative of greater psychological distress
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There is no reason to believe that this association remains 
consistent over time; therefore, our approach extends prior 
research [7, 23] by investigating the relationship empirically 
at multiple follow-up points in the data as follows:
where Hi
t denotes the parent’s i health-related quality of life 
measured by the HUI2 index score at time t = 0, 1, 2 for 
baseline, 6 and 12 months; Hj
t denotes the adolescent’s j 
HRQoL at time t measured by the overall EQ-5D-3L index 
score; Zj
0 is a vector of baseline characteristics of the adoles-
cent such as age, sex, type of self-harm event and total num-
ber of self-harm events; Ci
0 is a vector of baseline character-
istics of the parent such as sex and mental health measured 
by the GHQ-12; αt is the intercept, 훽 t
1
,… , 훽 t
3
 are the slope 
parameters and ɛi
t is the error term with 휀t
i
∼ N(0, 1) . The 
distribution of the utility of the parent is skewed to the left, 
thus we estimate all regression models using Tobit models.
The estimated coeicients were similar to those from the 
ordinary least-squares regressions both in magnitude and 
sign. We initially ran Model 1 including demographic con-
trols for both the adolescent (age, sex) and the parent (age). 
To account for the heterogeneity observed in adolescents’ 
parents, we subsequently ran Model 2 controlling for other 
adolescent characteristics (Hopelessness Scale for Children 
score, type of self-harm) and family characteristics from 
the parent’s perspective (Family Questionnaire, McMaster 
Family Assessment Device) as well as the parent’s GHQ-12. 
We supplemented this simplistic association analysis with a 
more causal understanding of the impact of a positive change 
in the adolescent’s health over time on a parent’s HRQoL in 
line with Bhadhuri et al. [43]. We included a binary vari-
able, taking the value 1 if the adolescent’s EQ-5D-3L score 
improved between baseline and follow-up, but this parameter 
was not signiicant and did not impact on the results.2
3.2  Parental Health Spillover in Cost‑Efectiveness 
Analysis: Five Alternative Quantiications
The base-case CEA considers the incremental costs and 
QALYs associated with FT vs. TAU as an intervention for 
self-harming adolescents. We are interested in quantifying 
the health spillover efects to the parent in the CEA, which 
can be used as an extra QALY gain inlating the adolescent’s 
QALY gain. Using the regression model presented in Eq. (1) 
as a starting point, we suggest four alternative quantiica-
tion methods to evaluate parental health spillover. We also 
consider a ifth quantiication with a direct measurement of 



















3.2.1  Relative Health Spillover (Quantiication 1)
The estimated parameter 훽̂ t
1
 in Eq. (1) can be used to extract 
a spillover coeicient of an adolescent’s health utility on 
parents. Assuming policy makers are interested in account-
ing for broad health beneits independently of the treatment 






 represent a utility gain 
for the parent at each time point, which can be transformed 
into a QALY gain using the area under the curve approach 
as follows:
If the relationship between the adolescent’s and parent’s 
HRQoL remains constant over time, the parameter 훽̂ t
1
 repre-
sents the full QALY gain, which is similar to what Al-Janabi 
et al. [24] called relative spillover.
3.2.2  Relative Health Spillover Per Treatment Arm 
(Quantiication 2)
One might suggest that we should also account for the het-
erogeneity in the parental health spillover according to the 
treatment received, especially because parents are directly 
involved in the FT arm, but not systematically involved in 
TAU.3 In this case, the parameter 훽̂ t
1
 will also vary by treat-
ment arm. Let us consider the estimated parameter 훽̂ t,FT
1
 , 
where FT = 0 when Eq. (1) is run on the sample of ado-
lescents receiving TAU and FT = 1 when it is run on those 
receiving FT. Three estimated health spillover coeicients 
(one for each time point) within each treatment arm can be 
used to quantify a utility gain for the parent, and then trans-



















































× 0.5 with FT = {0, 1}.
2 Results available upon request.
3 TAU included supportive therapy/counselling (25.1%), cognitive-
behavioural therapy (17.4%), family work (11.5%), formal systemic 
FT (10.7%) and various other therapies.
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3.2.3  Absolute Health Spillover (Quantiication 3)
Considering the primary outcome of the study was reducing 
repetitions of self-harm over 12 months, one could argue 
that measuring spillover coeicients according to the inal 
primary outcome provides an absolute health spillover for 
the parent. Contrary to Quantiication 1, Eq. (1) is now run 
separately on the sub-sample of adolescents who did not 
have a repeated self-harm at 12 months and on those who did 
self-harm again. The two sets of estimated health spillover 
coeicients 훽̂ t,SH
1
with SH = {0, 1} are used to generate an 
absolute QALY gain for the parent as follows:
3.2.4  Absolute Global Health Spillover Per Treatment Arm 
(Quantiication 4)
The absolute QALY gain for the parent could additionally 
account for the heterogeneity in health spillover according 
to treatment. The health spillover is measured using the esti-
mated coeicient 훽̂ t,SH,FT
1
 estimating Eq. (1) on four diferent 
sub-samples of adolescents.
3.2.5  Additive Accrued Health Beneits (Quantiication 5)
Using prior empirical studies, [20–22] health spillover 
could also be measured using an additive approach where 
the QALY gain of each individual in the dyad adolescent/
parent is independently calculated and then the two QALY 
gains are summed. Our case study uses two diferent HRQoL 
instruments for the adolescent and the parent. If  HUIt repre-
sents the parent’s health state utility value at each time point, 





























































× 0.5 with SH
















It is worthwhile to note that we assume that the QALYs 
as generated from HUI2 or EQ-5D-3L are of the same nature 
and meaning, and can be summed even if they are generated 
for two diferent individuals and produced from diferent 
instruments. This assumption follows from the foundation 
of resource allocation decisions in health according to which 
QALY provides an equal valuation between individuals and 
healthcare interventions of health improvement, indepen-
dently of the HRQoL instrument being used to measure 
quality of life.
3.3  Parental Health Spillovers in Cost‑Efectiveness 
Analysis: A New Perspective
In addition to all possible quantification methods to 
account for parental health spillover outlined in the previ-
ous section, we propose an additional method. While in 
the context of the economic evaluation of meningitis vac-
cination, Al-Janabi et al. [23] proposed a unique health 
spillover estimate that was applied to each family member 
afected or a health spillover estimate according to their 
proximity to the patient, we believe that this would not be 
appropriate in our case study. Three arguments motivate 
our viewpoint.
First, a single utility value would deny the heterogeneity 
observed in parents’ characteristics at baseline and their 
potential to beneit over the duration of the study accord-
ing to their level of engagement in the treatment, whether 
this is FT or TAU. From a clinical viewpoint, it would be 
expected that FT has an impact on other members of the 
family irrespective of whether those members attended the 
therapy sessions or whether there was any change in the 
self-harming adolescent. If therapy leads to those attending, 
behaving or communicating diferently, this will inevita-
bly impact others they relate to. The magnitude and even 
the direction of such impacts will vary from one family 
member to another, but cannot be ignored. Second, the 
treatment arm itself might impact on the parent’s health 
independently from the adolescent’s health improvement; 
in the SHIFT trial, for a number of secondary outcomes, 
caregivers reported signiicantly better outcomes than the 
adolescents [14]. Third, as part of a trial, several repeated 
observations of health utilities are available and it appears 
important to account for all the available repeated informa-
tion when quantifying spillover.
These arguments would lead us to consider the additive 
approach (where the QALY gain of each individual in the 
dyad adolescent/parent is independently calculated) appeal-
ing. At the same time, it is important to ensure that such 
aggregation does not lead to a decision that deteriorates the 
health of the adolescent, or more generally, of the patient in 
the irst place. There are clear value judgements about the 
priority assigned to the identiied patient, who is judged the 
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most important individual to beneit from a treatment, while 
the inclusion of health spillover efects for other individuals 
are of secondary purpose.
For this reason, we propose that health gains are aggregated 
at the household level if and only if the QALY gain for the 
patient is positive or equal to zero. When the QALY gain for 
the patient is positive, we need to identify a means of adjusting 
for the parental health spillover so that the patient’s health gain 
remains a priority for the healthcare decisions to be made. The 
concept of an equivalence scale (ES) as we will refer to from 
now on, has been used in economics to measure social welfare 
and adjusts the income of all household members account-
ing for the size of the household and the age of its members 
[44–46]. In our context, an ES would allow the adjustment 
of all health gains for the rest of the household as an addi-
tional individual equivalent QALY or utility gain where all 
the household members (including the patient) are accounted 
for. The ES transforms a distribution of observed QALY gains 
across heterogeneous household members into a household 
health gain. This adjusted health spillover can then simply be 
summed to the QALY gain of the patient in the CEA.
Following Buhmann et al. [44], let us consider that Q 







where hr equals the health spillover for each family relative r, 
R is the number of family relatives with an observed QALY 
or utility gain and a is the elasticity of the ES rate, which 
varies between 0 (when the health spillover is unadjusted 
and equivalent to a simple sum of the QALY gain available) 
and 1 (when a per capita QALY is used). The value of a 
is deined according to the importance given to the QALY 
gain of the family members beyond the patient (e.g. if a = 0, 
the family members are as important as the patient and this 
would be equivalent to quantiication 5). In our alternative 
speciications, we consider ive examples of quantiication 
of health spillover using an ES where a = {0, 0.3, 0.5, 0.8, 1}.
4  Results
4.1  Regression Models
Descriptive statistics are presented in Table 2. At baseline, 
more than two thirds of the adolescents were female with 
about three self-harm episodes over the duration of the trial. 
Self-harm was caused by self-injury for over 70% of the 
adolescents with more than 50% reporting some problems 
with anxiety/depression. For parents, 86% were mothers 
with an average age of 42 years (see Table 3). Parent’s aver-
age GHQ-12 was 8.52 (standard deviation 5.38), which is 
Table 2  Adolescents’ 
characteristics at baseline
EQ-5D-3L EuroQoL 5 Dimensions 3 Levels, FT family therapy, SD standard deviation, TAU treatment as 
usual
a Hopelessness scale score was not available for 11 adolescents
Characteristics All (N = 754) TAU (N = 371) FT (N = 383)
Sex, n (%)
 Male 93 (12) 48 (13) 45 (12)
 Female 661 (88) 323 (87) 338 (88)
Age, years, n (%)
 11–14 396 (53) 195 (53) 201 (52)
 15–17 358 (47) 176 (47) 182 (48)
Centre, n (%)
 Yorkshire 272 (36) 135 (36) 137 (36)
 Manchester 267 (35) 132 (36) 135 (35)
 London 215 (29) 104 (28) 111 (29)
Total no. of self-harm episodes, mean (SD) 2.92 (21.51) 3.26 (28.59) 2.60 (10.95)
Type of index episode, n (%)
 Self-poisoning 170 (23) 83 (22) 87 (23)
 Self-injury 533 (71) 262 (71) 271 (71)
 Combined 51 (7) 26 (7) 25 (7)
Source of referral (from hospital), n (%)
 Yes 274 (36) 130 (35) 144 (38)
 No 480 (64) 241 (65) 239 (62)
EQ-5D-3L score (overall), mean (SD) 0.68 (0.27) 0.68 (0.26) 0.68 (0.28)
Hopelessness Scale for Children  scorea, mean (SD) 7.39 (4.26) 7.21 (4.29) 7.56 (4.22)
Parental Health Spillover in Cost-Effectiveness Analysis
within the distressed range (4–12) but lower than the level 
of psychological distress observed in a sample of caregivers 
of a dependent relative [47].
Table 4 shows the mean utility scores for adolescents and 
their parent at baseline, 6 and 12 months, overall and by 
treatment arm. For the adolescents, utility scores increase 
monotonically over the 12 months and regardless of the 
treatment arm. Diferences in utility scores between arms 
were signiicant at 6 and 12 months favouring FT. The dif-
ference from baseline appears to be slightly larger in FT 
than in TAU (on average 0.145 vs. 0.095). The parent’s util-
ity also shows an increase in the overall HUI2 score at 6 
and 12 months from baseline; this increase however is much 
smaller than for the adolescent (on average 0.045 vs. 0.12) 
and is not signiicant when distinguished by treatment arm.
Table 3  Parents’ characteristics 
at baseline
FT family therapy, GHQ General Health Questionnaire, HUI Health Utility Index, SD standard deviation, 
TAU treatment as usual
a Age was not available for 81 caregivers
b McMaster Family Assessment Device was not available for 9 parents
c Family Questionnaire was not available for 1 parent
d Parent GHQ score was not available for 3 parents
Characteristics All (N = 754) TAU (N = 371) FT (N = 383)
Sex, n (%)
 Male 89 (12) 47 (13) 42 (11)
 Female 665 (88) 324 (87) 341 (89)
Relationship to adolescent, n (%)
 Father 85 (11) 47 (13) 38 (10)
 Foster parent 2 (0) 1 (0) 1 (0)
 Guardian 11 (1) 3 (1) 8 (2)
 Mother 649 (86) 318 (86) 331 (86)
 Step-father 2 (0) 0 (0) 2 (1)
 Step-mother 5 (1) 2 (1) 3 (1)
Agea, years, mean (SD) 42.38 (6.42) 42.40 (6.18) 42.36 (6.64)
HUI score (overall), mean (SD) 0.71 (0.28) 0.70 (0.28) 0.72 (0.27)
McMaster Family Assessment  Deviceb, mean 
(SD)
2.20 (0.37) 2.21 (0.37) 2.20 (0.36)
Family  Questionnairec, mean (SD) 52.86 (10.75) 52.88 (10.79) 52.84 (10.72)
Parent  GHQd, mean (SD) 5.70 (4.07) 6.07 (4.07) 5.33 (4.04)
Table 4  Adolescent’s and parent’s health-related quality of life by time period (N = 754)
EQ-5D-3L EuroQoL 5 Dimensions 3 Levels, FT family therapy, HUI Health Utility Index, SD standard deviation, TAU treatment as usual
**p < 0.01; ***p < 0.001
Baseline 6 months 12 months
Overall, mean (SD)
Adolescent’s EQ-5D-3L score 0.68 (0.27) 0.78 (0.17) 0.80 (0.19)
Parent’s HUI score 0.71 (0.28) 0.76 (0.23) 0.78 (0.23)
Family therapy
Adolescent’s EQ-5D-3L score 0.68 (0.28) 0.80 (0.17) 0.81 (0.19)
Parent’s HUI score 0.72 (0.27) 0.77 (0.23) 0.78 (0.23)
Treatment as usual
Adolescent’s EQ-5D-3L score 0.68 (0.26) 0.76 (0.17) 0.78 (0.18)
Parent’s HUI score 0.70 (0.28) 0.76 (0.22) 0.78 (0.23)
Difference FT vs. TAU, mean (SD)
Adolescent’s EQ-5D-3L score − 0.003 (0.20) 0.043*** (0.01) 0.036** (0.14)
Parent’s HUI score 0.019 (0.02) 0.014 (0.03) 0.000 (0.02)
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Table 5 presents the Tobit regression results of the par-
ent’s HRQoL; the association between the parent’s and ado-
lescent’s health varies across time points and model specii-
cations. We ind a signiicant and positive association with 
the parent’s health at 6 months and 12 months in Model 2 
while in Model 1, the parent’s health is positively associ-
ated with the adolescent’s HRQoL at 6 months only. This 
is in line with prior studies on the experience of parents’ 
caregiving for an ill child [5, 7, 48], and carers of people 
with mental health disorders [3].
The parent’s HRQoL at every time point also appears to be 
negatively associated with a higher score of emotion within the 
family, of poor family functioning and of psychological dis-
tress as measured by GHQ-12, all three measured at baseline. 
The strong association between a parent’s utility and GHQ-
12 has also been shown in other studies [49]. Furthermore, 
parent’s health is positively and signiicantly associated with 
an adolescent’s higher score of hopelessness; however, this 
association substantially reduces in magnitude and signiicance 
over time.
4.2  Spillover Efects in Cost‑Efectiveness Analysis
Table 6 presents the incremental cost-efectiveness ratios 
(ICERs) and their respective probabilities of cost-efective-
ness using the base-case analysis when only the adolescent’s 
QALY gain is considered along with the ive regression-
based alternative spillover quantiications4 and the ES-based 
spillover quantiication with ive alternative elasticity values. 
Costs used in the analysis are summarised in Table 10 of the 
“Appendix”. Because we did not collect healthcare costs for 
the parent, we note that the costs for each ICER are strictly 
identical and it is only the level of QALY gain that varies.
Results from the base-case analysis indicate that ado-
lescents in FT incurred £1207 higher costs on average 
and gained 0.030 extra QALYs than the adolescents in 
Table 5  Relative health spillover: results of Tobit regression model of the parent’s health-related quality of life with adolescent’s EuroQoL 5 
Dimensions 3 Levels (EQ-5D-3L) score (full sample with imputations for missing data)
GHQ General Health Questionnaire, HUI Health Utility Index, ref. reference, SH self-harm
*p < 0.05; **p < 0.01; ***p < 0.001
Variables Model 1 Model 2
Baseline 6 months 12 months Baseline 6 months 12 months
Adolescent
 EQ-5D-3L − 0.0077 0.2913*** 0.0881 0.0558 0.2997*** 0.1272**
 Female 0.0895* 0.0516* 0.0332 0.0470 0.0314 0.0136
 Age 15–17 years vs. 11–14 years − 0.0231 0.0183 0.0162 0.0130 0.0078 0.0398
Type of index episode (ref. self-poisoning)
 Self-injury 0.0336 0.0752*** 0.0119
 Combined 0.0495 0.0594 0.0078
 Repeated SH episodes (ref. >3 events) − 0.0357 − 0.0565 0.0263
 Hopelessness Scale for Children score 0.0108*** 0.0047* 0.0050*
Parent
 McMaster Family Assessment Device − 0.1031** − 0.0702** − 0.0763*
 Family Questionnaire − 0.0033** − 0.0027** − 0.0027*
 Parent GHQ − 0.0378*** − 0.0157*** − 0.0150***
 Female − 0.1062** − 0.0550* − 0.0511 − 0.0218 − 0.0213 − 0.0101
Centre
 Manchester − 0.0865*** − 0.0237 − 0.0097
 London − 0.0781** − 0.0062 0.0045
 Constant 0.8176*** 0.5914*** 0.7564*** 1.3256*** 0.9341*** 0.9594***
Sigma 0.3382 0.2536 0.2900 0.2702 0.2267 0.2699
Observations 754 754 754 731 731 731
Pseudo R-squared 0.017 0.084 0.010 0.426 0.459 0.151
4 Quantiication 1 is based on the Tobit regression results presented 
in Table 5. Quantiication 2 is based on the Tobit regression results 
presented in Table 7 of the “Appendix”. Quantiication 3 is based on 
the Tobit regression results presented in Table 8 of the “Appendix”. 
Quantiication 4 is based on the Tobit regression results presented in 
Table 9 of the “Appendix”.
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Table 6  Incremental cost-
efectiveness ratios (ICERs) 
with alternative spillover 
quantiications




TAU 3750.59 (198.34) 0.745 (0.008)
FT 4957.75 (194.13) 0.774 (0.008)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.030*** (0.011) 40,453.30 (0.080–0.263)
Quantification 1: Relative health spillover (Model 2, Table 5)
TAU 3750.59 (198.34) 0.940 (0.008)
FT 4957.75 (194.13) 0.970 (0.008)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.030*** (0.011) 40,453.30 (0.073–0.284)
Quantification 2: Relative health spillover per treatment arm (Model 2, Table 6)
TAU 3750.59 (198.34) 1.001 (0.008)
FT 4957.75 (194.13) 0.934 (0.008)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) − 0.067***(0.011) Dominated (0.000–0.000)
Quantification 3: Absolute health spillover (Model 2, Table 7)
TAU 3750.59 (198.34) 0.943 (0.008)
FT 4957.75 (194.13) 0.972 (0.008)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.030** (0.012) 40,838.11 (0.083–0.267)
Quantification 4: Absolute health spillover per treatment arm (Model 2, Table 8)
TAU 3750.59 (198.34) 1.056 (0.019)
FT 4957.75 (194.13) 0.905 (0.010)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) − 0.150***(0.021) Dominated (0.001–0.004)
Quantification 5: Additive health spilloverb
TAU 3750.59 (198.34) 1.492 (0.015)
FT 4957.75 (194.13) 1.536 (0.014)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.044** (0.020) 27,166.45 (0.297–0.568)
Equivalence scale health spillover with a = 0
TAU 3750.59 (198.34) 1.492 (0.015)
FT 4957.75 (194.13) 1.536 (0.014)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.044** (0.020) 27,166.45 (0.279–0.539)
Equivalence scale health spillover with a = 0.3
TAU 3750.59 (198.34) 1.351 (0.013)
FT 4957.75 (194.13) 1.393 (0.013)
Incremental costs Incremental QALY
FT vs. TAU 1,207.16*** (277.53) 0.042** (0.018) 28,951.77 (0.245–0.531)
Equivalence scale health spillover with a = 0.5
TAU 3750.59 (198.34) 1.273 (0.012)
FT 4957.75 (194.13) 1.313 (0.012)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.040** (0.020) 30,058.05 (0.202–0.487)
Equivalence scale health spillover with a = 0.8
TAU 3750.59 (198.34) 1.174 (0.011)
FT 4957.75 (194.13) 1.212 (0.011)
Incremental costs Incremental QALY
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TAU, which is equivalent to an extra 10.95 days of per-
fect health annually. The ICER from this analysis (£40,453 
per QALY) is above the recommended threshold range 
speciied for NICE decision making in England and Wales 
(£20,000–£30,000 per QALY gain), indicating that FT is 
unlikely to be cost-efective. When considering the relative 
parental health spillover independently of the treatment arm 
using quantiication 1, the ICER is almost identical to the 
one obtained from the base-case analysis. However, when 
accounting for the direct involvement of the parents in the 
FT arm (quantiication 2), parents and adolescents continue 
to incur higher costs on average but with 24.5 fewer days of 
perfect health (loss of 0.067 QALYs annually) than those in 
TAU and therefore indicating that FT is dominated by TAU.
The ICER remains above the nationally recommended 
threshold when we control for the absolute parental health 
spillover using the number of repeated self-harm events at 
12 months (£40,838), implying that FT is not cost efective. 
If we further control for any heterogeneity in the absolute 
parental health spillover, FT is dominated by TAU with ado-
lescents and parents in the FT arm incurring 54.8 fewer days 
of perfect health (loss of 0.150 QALYs annually) than those 
in the TAU arm. Any of the regression-based quantiications 
indicate that FT is unlikely to be cost efective. However, 
the ICER reduces to £27,167 per QALY when we simply 
sum the adolescent’s and parent’s QALYs (quantiication 5), 
demonstrating a potential for FT to bring 16.1 extra days at 
full health annually for both the adolescent and the parent 
and a value within the NICE threshold range.
As expected, quantiication 5 is equivalent to the quanti-
ication with an ES using an elasticity of a = 0. The value of 
the elasticity a directly impacts on the average QALY gains, 
and the higher the elasticity, the lower the cumulated QALY 
gain and thus the higher the ICER. For smaller values of the 
elasticity a (less than 0.5), the quantiications using an ES 
show an ICER within the NICE cost-efectiveness range. 
The probability of FT to be cost efective is higher when 
using an ES to quantify spillover than with regression-based 
spillover quantiications; at £20,000 it is between 16 and 
28% with an ES vs. 0–7% with regressions. At £30,000, it 
respectively reaches 43–54% vs. 0–28%.
It is important to note that with any quantification 
method, both cost diferences between FT and TAU and 
QALY diferences are signiicant. The same analyses were 
performed on the complete case sample to test the sensitivity 
of the results to missing data imputations (see Table 11 of 
the “Appendix”). The ICER estimations for each spillover 
quantiication are all larger (between £34,071 and £45,842) 
with broader standard deviations for both costs and QALYs. 
It is remarkable that the diferences between quantiications 
present the same pattern as the main analysis.
5  Discussion
We showed that a parent’s HRQoL is associated with the 
health of a self-harming adolescent. We investigated how 
health spillover for the parent could be included in CEA using 
alternative quantiications based on estimated coeicients and 
QALY valuations. Sensitivity analyses revealed that the valu-
ation technique had a considerable impact on the magnitude 
of the QALY and could change the inference about the most 
cost-efective alternative in a trial. We made two propositions 
in this article. Proposition 1 suggests that health gains are only 
aggregated at the household level when the QALY gain for 
the patient is positive or equal to zero. Proposition 2 suggests 
the use of an ES to convert a distribution of observed health 
spillover across other household members into an extra health 
CE , FT family therapy, QALY quality-adjusted life-year, SE standard error, TAU treatment as usual
*p < 0.05; **p < 0.01; ***p < 0.001
a The cost-efectiveness probabilities of FT at £20,000 and £30,000 were estimated using the Stata com-
mand tsbceprob (Ng et al., 2013 [56])
b The adolescent’s and parent’s QALYs are summed, this is equivalent to a = 0
Table 6  (continued) Scenario Costs, £ (SE) QALY (SE) ICER (£/QALY) CE probabilities 
of FT (£20,000–
£30,000)a
FT vs. TAU 1207.16*** (277.53) 0.038** (0.015) 31,581.72 (0.169–0.475)
Equivalence scale spillover with a = 1
TAU 3750.59 (198.34) 1.118 (0.010)
FT 4957.75 (194.13) 1.155 (0.010)
Incremental costs Incremental QALY
FT vs. TAU 1207.16*** (277.53) 0.037** (0.015) 32,504.48 (0.164–0.426)
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gain to be added to the patient’s QALY gain. We illustrated the 
use of an ES with a set of alternative elasticity values. There 
are several advantages with the use of an ES. First, an ES has 
been widely used in the literature to measure household social 
welfare [44–46]. Second, health spillover measured either as a 
QALY gain from a utility score or a utility parameter generated 
from a regression model could be summed and transformed 
into an extra health gain using the ES. Third, the ES adapts to 
data availability and thus every family relative with observed 
health outcomes can be included. Finally, one could transform 
easily the ES to account for family members’ proximity to the 
patient including an individual weight in the same way it is 
achieved with income equivalence scales.5 This methodologi-
cal proposition will require further scrutiny in future research.
5.1  Limitations
Our study presents limitations. The trial study used two dif-
ferent HRQoL instruments to measure the adolescent and 
the parent’s quality of life. For the purpose of the spillover 
quantiication, we assumed that utilities and QALYs gener-
ated from two diferent generic measures were of the same 
nature and meaning and could be combined. However, these 
two measures are quite diferent in descriptive content and in 
valuation technique. While the EQ-5D covers dimensions of 
physical, mental and general health and is valued with Time 
Trade-Of, HUI2 additionally considers impairments in vision, 
hearing, and dexterity and is valued using standard gamble and 
visual analogue scaling. Research has shown a moderate level 
of agreement between HRQoL measures in various condition-
speciic groups [50–53]. The assumption according to which 
the two preference-based measures can be combined in our 
spillover quantiications could potentially be biased. For exam-
ple, if EQ-5D-3L tends to provide lower mean utility estimates 
than HUI2, this would imply for our study that quantiication 5 
and the ES quantiication with a = 0 lead to an aggregation of 
health gains where the parent’s QALY gain from the interven-
tion is relatively higher than for the adolescent’s (patient’s) 
QALY gain, and thus the patient is not the main beneiciary 
(though respecting proposition 1 ensures that the patient is the 
priority for the healthcare decision making). In this context, 
head-to-head comparisons between preference-based HRQoL 
instruments will be useful to develop potential measurement 
corrections to ensure comparability between utilities and 
QALYs when measuring health spillover.
Methodologically, the reverse correlation with a focus 
on the impact of a parent’s health on an adolescent’s health 
could have been of interest to study. Moreover, several 
authors [13, 17, 54] have argued that potential healthcare 
cost savings are transferred to others when treating one fam-
ily member using family-based psychotherapy; it would be 
ideal to include the healthcare resource use of the parent had 
they been available in the data.
Conceptually, we investigated how social externalities 
such as the health efects on other individuals could be intro-
duced into the framework of a CEA; to some extent, this 
questions whether a cost-utility analysis is appropriate or 
whether a cost-beneit analysis with distributional weights 
should be considered. We did not enter into this debate and 
assumed that a cost-utility analysis would remain the pre-
ferred method for the health spillover quantiication [55].
Admittedly, our proposition to rely on an ES is a prag-
matic choice. The adoption of a unique scale that would be 
identical for any CEA would have the advantage of facilitat-
ing the generation of evidence that is comparable between 
individuals and between cost-utility analyses.
6  Conclusions
There is no consensus on how health spillover of illness 
on family members or caregivers should be measured and 
valued for cost-efectiveness analyses. A household welfare 
function along with an equivalence scale could be used to 
adjust health spillovers and generate a health gain within the 
family to be added to the patient’s QALY gain.
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Table 7  Relative health spillover per arm: results of Tobit regression model of parent’s health-related quality of life with adolescent’s EuroQoL 
5 Dimensions 3 Levels (EQ-5D-3L) score per treatment arm (full sample with imputations for missing data)
GHQ General Health Questionnaire, ref. reference, SH self-harm
*p < 0.05; **p < 0.01; ***p < 0.001
Variables Treatment as usual Family therapy
Baseline 6 months 12 months Baseline 6 months 12 months
Adolescent
 EQ-5D-3L 0.0612 0.3189*** 0.3261*** 0.0596 0.3100*** − 0.0401
 Female 0.0563 − 0.0289 − 0.0192 0.0484 0.1131** 0.0595
 Age 15–17 years vs. 11–14 years − 0.0480 − 0.0050 − 0.0072 0.0245 0.0234 0.0810**
Type of index episode (ref. self-poisoning)
 Self-injury 0.0096 0.0448 0.0263 0.0661 0.1175*** 0.0123
 Combined 0.0563 0.0679 − 0.0049 0.0472 0.0691 0.0069
 Repeated SH episodes (ref. > 3 events) − 0.0290 − 0.0395 0.0479 − 0.0873 − 0.0876* 0.0013
 Hopelessness Scale for Children score 0.0115** 0.0059* 0.0102** 0.0085** 0.0033 0.0008
Parent
 McMaster Family Assessment Device − 0.0244 − 0.0378 − 0.0112 − 0.1892*** − 0.1163** − 0.1340**
 Family Questionnaire − 0.0054** − 0.0034** − 0.0018 − 0.0010** − 0.0021 − 0.0026
 Parent GHQ − 0.0390*** − 0.0176*** − 0.0178*** − 0.0354*** − 0.0137*** − 0.0102**
 Female − 0.0261 − 0.0282 0.0038 − 0.0310 − 0.0116 − 0.0331
Centre
 Manchester − 0.0640 − 0.0081 − 0.01812 − 0.1212*** − 0.0465 − 0.0178
  London − 0.0726 − 0.0160 0.0049 − 0.0836** − 0.0017 − 0.0276
  Constant 1.2351*** 1.0202*** 0.6121** 1.4349*** 0.8424*** 1.1679***
Sigma 0.2795 0.2348 0.2534 0.2560 0.2278 0.2576
Observations 359 359 359 372 372 372
Pseudo R-squared 0.407 0.358 0.246 0.481 0.439 0.208
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Appendix
See Tables 7, 8, 9, 10 and 11.
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Table 8  Absolute health spillover: results of Tobit regression model of the parent’s health-related quality of life with adolescent’s EuroQoL 5 
Dimensions 3 Levels (EQ-5D-3L) score per repeated self-harm (SH) event at 12 months (full sample with imputations for missing data)
GHQ General Health Questionnaire, HUI Health Utility Index, ref. reference, SH self-harm
*p < 0.05; **p < 0.01; ***p < 0.001
Variables No repeated SH at 12 months Repeated SH at 12 months
Baseline 6 months 12 months Baseline 6 months 12 months
Adolescent
 EQ-5D-3L 0.0389 0.3023*** 0.1567** 0.0923 0.3763*** 0.0708
 Female 0.0350 0.0240 − 0.0141 0.1071 0.0788 0.1515
  Age 15–17 years vs. 11–14 years − 0.0026 0.0147 0.0311 0.0553 − 0.0049 0.0661
Type of index episode (ref. self-poisoning)
  Self-injury − 0.0022 0.0571* − 0.0289 − 0.0492* 0.1263** 0.1093*
  Combined 0.0186 0.0628 − 0.0586 − 0.0856* 0.0735 0.1389
  Repeated SH episodes (ref. > 3 events) − 0.0094 − 0.0344 0.0486 − 0.2188** − 0.1219** − 0.0310
 Hopelessness Scale for Children score 0.0084** 0.0027 0.0030 0.0179** 0.0131** 0.0160**
Parent
 McMaster Family Assessment Device − 0.0977** -0.0706* − 0.0878* − 0.1269* − 0.1029 − 0.0518
  Family Questionnaire − 0.0032* -0.0027* − 0.0017 − 0.0038 − 0.0036 − 0.0057*
  Parent GHQ − 0.0346*** -0.0143*** − 0.0123*** − 0.0434*** − 0.0169** − 0.0148*
  Female − 0.0309 0.0001 -0.0037 0.0023 − 0.0826 − 0.0685
Centre
  Manchester − 0.0892** -0.0033 0.0178 − 0.0492 − 0.0838 − 0.0567
  London − 0.0726** 0.0044 0.0227 − 0.0856 − 0.0482 − 0.1284*
  Constant 1.3282*** 0.2900*** 0.5891*** 1.3456*** 0.7436*** 0.7164**
Sigma 0.2639 0.2215 0.2433 0.2730 0.2511 0.2814
Observations 536 536 536 195 195 195
Pseudo R-squared 0.407 0.376 0.189 0.526 0.417 0.273
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Table 9  Absolute health spillover per arm: results of Tobit regression 
model of the parent’s health-related quality of life with adolescent’s 
EuroQoL 5 Dimensions 3 Levels (EQ-5D-3L) score per repeated self-
harm (SH) event at 12  months and per arm treatment (full sample 
with imputations for missing data)
GHQ General Health Questionnaire, HUI Health Utility Index, ref. reference, YP
*p < 0.05; **p < 0.01; ***p < 0.001
Variables TAU FT
Baseline 6 months 12 months Baseline 6 months 12 months
No repeated self-harm
Adolescent
 EQ-5D-3L 0.0674 0.0878 0.3196*** 0.0352 0.4587*** 0.0039
 Female 0.0610 0.1585 − 0.0489 0.0180 0.0804 0.0309
 Age 15–17 years vs. 11–14 years − 0.0393 0.0195 − 0.0087 0.0228 0.0207 0.0661**
Type of index episode (ref. self-poisoning)
 Self-injury − 0.0041 0.2310*** 0.0276 0.0118 0.0620 − 0.0631
 Combined 0.1001 0.1639* − 0.0320 − 0.0489 0.0011 − 0.0862
 Repeated SH episodes (ref. >3 events) 0.0435 − 0.2209** 0.0666 − 0.0537 − 0.0446 0.0378
 YP Hopelessness Scale score 0.0119** 0.0103 0.0103*** 0.0053 0.0015 − 0.0027
Parent
 McMaster Family Assessment Device − 0.0160 − 0.1997*** − 0.0114 − 0.1765*** − 0.0762 − 0.1493***
 Family Questionnaire − 0.0049** − 0.0032 − 0.0016 − 0.0011 − 0.0018 − 0.0014
 Parent GHQ − 0.0368*** − 0.0107 − 0.0147*** − 0.0321*** − 0.0137*** − 0.0104**
 Female − 0.0609 − 0.1393 − 0.0031 − 0.0193 − 0.0040 0.0034
Centre
 Manchester − 0.0643 − 0.0569 0.0185 − 0.1220*** -0.0428 0.0120
 London − 0.0769 0.0175 0.0461 − 0.0716 0.0021 0.0113
 Constant 1.1704*** 1.5139 0.6429*** 1.4540*** 0.6033*** 1.1036***
Sigma 0.2746 0.2146 0.2443 0.2440 0.2098 0.2331
Observations 270 270 270 266 266 266
Pseudo R-squared 0.409 0.486 0.255 0.476 0.658 0.287
Repeated self-harm
Adolescent
 EQ-5D-3L 0.0388 0.6925*** 0.4393** 0.1371 0.0878 − 0.1647
 Female 0.0887 − 0.0019 0.1264 0.1378 0.1585 0.1815
 Age 15–17 y vs. 11–14 y 0.0918 0.0207 − 0.0065 0.0190 0.0195 0.1396**
Type of index episode (ref. self-poisoning)
 Self-injury 0.0143 − 0.0021 0.0234 0.1809** 0.2310*** 0.1810***
 Combined 0.0944 − 0.0241 0.0527 0.2296* 0.1639* 0.1468
 Repeated SH episodes (ref. >3 events) − 0.3173** − 0.0911 0.0686 − 0.1710 − 0.2209** − 0.1419
 Hopelessness Scale for Children score 0.0123 0.0128 0.0098 0.0200* 0.0103 0.0171**
Parent
 McMaster Family Assessment Device − 0.0071 0.0242 0.0267 − 0.2147* − 0.1997*** -0.0785
 Family Questionnaire − 0.0079* − 0.0042 − 0.0024 − 0.0001 − 0.0032 − 0.0078**
 Parent GHQ − 0.0452*** − 0.0212** − 0.0256** − 0.0466*** − 0.0107 − 0.0057
 Female 0.0489 − 0.0759 0.0217 − 0.1224 − 0.1393 − 0.2255
Centre
 Manchester 0.0287 − 0.1213 − 0.0984 − 0.0847 − 0.0569 − 0.0360
 London − 0.0270 − 0.0973 − 0.1149 − 0.1304 0.0175 − 0.0909
 Constant 1.4848*** 0.8156* 0.2465 1.4498*** 1.5139*** 1.4929***
Sigma 0.2697 0.2444 0.2608 0.2632 0.2142 0.2700
Observations 89 89 89 106 106 106














Table 10  Average healthcare provider costs by trial arm after imputations
A&E accident and emergency, FT family therapy, Max maximum, Min minimum, SD standard deviation, TAU treatment as usual
Costs, £ Baseline to 6 months 6–12 months
All TAU FT All TAU FT
Health and social services
 Mean (SD) 569.37 (857.95) 650.80 (868.23) 491.56 (841.82) 385.10 (693.05) 360.33 (672.93) 409.08 (712.06)
 Min 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Max 10,994.00 9648.00 10,994.00 5520.00 4894.00 5520.00
Hospital services (inpatient stays and 
A&E visits),
 Mean (SD) 62.61 (288.81) 58.66 (186.43) 66.38 (360.66) 38.60 (144.91) 30.61 (123.37) 46.34 (162.86)
 Min 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Max 6415.50 1411.41 6415.50 1283.10 1026.48 1283.1
Hospital outpatient visits
 Mean (SD) 241.01 (633.57) 236.66 (675.93) 245.22 (590.51) 246.88 (685.87) 254.36 (740.84) 239.64 (628.95)
 Min 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Max 6552.19 6552.19 3658.86 8522.76 8522.76 5035.13
Medication
 Mean (SD) 0.40 (7.62) 0.21 (3.10) 0.57 (10.24) 0.39 (7.58) 0.20 (2.91) 0.57 (10.24)
 Min 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
 Max 199.93 59.06 199.93 199.93 55.20 199.93
 S. Tubeuf et al.
Table 11  Incremental cost-
efectiveness ratios (ICERs) 
with alternative spillover 
quantiications (no imputations)




TAU (n = 73) 3475.22 (380.19) 0.756 (0.021)
FT (n = 133) 4568.081 (259.32) 0.779 (0.016)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.024 (0.027) 45,841.96 (0.219–0.353)
Quantification 1: Relative health spillover (Model 2, Table 5)
TAU (n = 73) 3475.22 (380.19) 0.955 (0.021)
FT (n = 133) 4568.081 (259.32) 0.979 (0.016)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.024 (0.027) 45,841.95 (0.242–0.393)
Quantification 2: Relative health spillover per treatment arm (Model 2, Table 6)
TAU (n = 73) 3475.22 (380.19) 1.059 (0.021)
FT (n = 133) 4568.081 (259.32) 0.882 (0.016)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) − 0.177 (0.027) Dominated (0.000–0.000)
Quantification 3: Absolute health spillover (Model 2, Table 7)
TAU (n = 73) 3475.22 (380.19) 0.955 (0.021)
FT (n = 133) 4568.081 (259.32) 0.980 (0.016)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.026 (0.026) 42,469.92 (0.225–0.406)
Quantification 4: Absolute health spillover per treatment arm (Model 2, Table 8)
TAU (n = 73) 3475.22 (380.19) 1.018 (0.028)
FT (n = 133) 4568.081 (259.32) 0.920 (0.017)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) − 0.097*** (0.031) Dominated (0.001–0.000)
Quantification 5: Additive health spilloverb
TAU (n = 73) 3475.22 (380.19) 1.537 (0.041)
FT (n = 133) 4568.081 (259.32) 1.569 (0.027)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.032 (0.047) 34,070.62 (0.545–0.455)
Equivalence scale health spillover with a = 0
TAU (n = 73) 3475.22 (380.19) 1.537 (0.041)
FT (n = 133) 4568.081 (259.32) 1.569 (0.027)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.032 (0.047) 34,070.62 (0.362–0.472)
Equivalence scale health spillover with a = 0.3
TAU (n = 73) 3475.22 (380.19) 1.390 (0.037)
FT (n = 133) 4568.081 (259.32) 1.421 (0.024)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.031 (0.042) 35,796.37 (0.337–0.455)
Equivalence scale health spillover with a = 0.5
TAU (n = 73) 3475.22 (380.19) 1.308 (0.034)
FT (n = 133) 4568.081 (259.32) 1.338 (0.023)
Incremental costs Incremental QALY
FT vs. TAU 1092.85** (449.22) 0.030 (0.040) 36,841.44 (0.326–0.443)
Equivalence scale health spillover with a = 0.8
TAU (n = 73) 3475.22 (380.19) 1.204 (0.031)
FT (n = 133) 4568.081 (259.32) 1.233 (0.021)
Incremental costs Incremental QALY
Parental Health Spillover in Cost-Effectiveness Analysis
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